Pro-resolving, docosahexaenoic acid-derived mediators have recently emerged as important potential therapeutic agents for the amelioration of complications arising from inflammation, such as vascular disease, asthma, acute lung injury and colitis. While resolvin D1 (RVD1), resolvin D2 (RVD2) and maresin 1 (MaR1) are established pro-resolvins, their mechanisms of action remain unclear. Here we show that, in LPS-stimulated primary human monocytes, RVD1, RVD2 and MaR1 each suppress the release of pro-inflammatory cytokines (TNF, IL-1b, IL-8) and the innate/adaptive bridging cytokine, IL-12 p40, while simultaneously augmenting the production of the anti-inflammatory cytokine, IL-10. Such resolving activity is accompanied by the increased phosphorylation (enhanced anti-inflammatory state) of glycogen synthase kinase 3b (GSK3b) along with increased phosphorylation (activation) of Akt, SGK1 and CREB but not MAPK-related molecules. Gain and loss of function experiments confirm a key role for GSK3b and CREB in the antiinflammatory actions of resolvins. These results suggest that induction of the GSK3b anti-inflammatory axis is a common mechanism of action for RVD1, RVD2 and MaR1.
Introduction
There are multiple potentially convergent endogenous pathways that serve to limit inflammation and promote its resolution, thereby protecting the host from collateral damage. Such innate braking systems include the a7 acetylcholine receptor-dependent cholinergic; glycogen synthase kinase 3b (GSK3b); serum and glucocorticoid-regulated kinase 1 (SGK1); and Wnt antiinflammatory signaling axes. [1] [2] [3] [4] [5] The identification of omega-3 polyunsaturated fatty acid-derived resolving mediators, including the docosahexaenoate metabolites resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z, 15E,19Z-docosahexaenoic acid; RVD1), resolvin D2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid; RVD2) and maresin-1 (7R,14Sdihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid; MaR1), have added to the emergent understanding that the resolution of inflammation is highly dynamic. [6] [7] [8] [9] In vivo, RVD1, RVD2 and/or MaR1 have been shown to suppress pro-inflammatory cytokine production during multiple inflammatory conditions with protective consequences, including experimental uveitis, 10 hepatic ischemia/reperfusion injury, 11 peritonitis, 12 periodontitis, 13 acute lung injury, [14] [15] [16] [17] [18] colitis, 19 ,20 endometriosis 21 and endotoxic shock. 22 Resolvins have also been reported to abet caspasedependent neutrophil apoptosis, 14, 23 to augment efferocytosis 24, 25 and to promote the de novo generation of regulatory T cells. 26 All such processes are associated with the resolution of inflammation.
In vitro, RVD1, RVD2 and/or MaR1 suppress proinflammatory cytokine release in several innate immune cell types that have been exposed to variant inflammatory mediators, such as bronchial epithelial cells, 27, 28 corneal epithelial cells, 29 macrophages 30 and gingival fibroblasts. 31 Furthermore, resolving mediators, particularly RVD1 and MaR1, have been shown to suppress NF-kB activation in cells such as microglia, 32, 33 smooth muscle cells 34 and vascular endothelial cells, 35 as well as in several inflammatory disease animal models, including acute lung injury, 15, 18, 36 colitis 19 and sepsis. 37 However, the events leading to inhibition of NF-kB signaling have yet to be fully elucidated.
GSK3b is constitutively active and promotes inflammation in the context of TLR engagement. However, phosphorylation of GSK3b at Ser9 results in inhibition of the production of pro-inflammatory cytokines. 1, 2, 38 Zhang et al. 11 recently suggested that RVD1 suppression of pro-inflammatory cytokines and attenuation of hepatic ischemia/reperfusion injury is mediated, at least in part, by a mechanism involving enhanced phosphorylation of Akt. Several other groups have also reported that PI3K-Akt-related signaling events are key to the protective efficacy of RVD1 protection against inflammatory damage. 16, 39, 40 Further, resolvin E1 (5S,12R,18R)-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; RVE1) and lipoxin A4 (5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid; LXA4) have both been reported to influence the activation state of Akt. 41, 42 PI3K is an activator of Akt, while Akt is an established kinase inactivator of the central mediator of inflammation, GSK3b. 1, 2, 38 Therefore, we hypothesized that the pro-resolving activities of RVD1, RVD2 and MaR1 may involve the inactivation of GSK3b and thus augmentation of GSK3b anti-inflammatory axis. We set out to test this hypothesis in LPSstimulated primary human monocytes.
Materials and methods Materials
Monocyte isolation kits were from Miltenyi Biotec (Auburn, CA, USA). RPMI Complete (RPMI 1640 medium supplemented with FBS, 2-mercaptoethanol, sodium pyruvate, L-glutamine and HEPES) was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Ultrapure LPS from Escherichia coli 0111:B4 was purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-phospho-NF-kB p65 (Ser536), pGSK3b (Ser9), pCREB (Ser133), pERK1/2 (Thr202/Tyr204), pSAPK/JNK (Thr183/Tyr185), p-p38 MAPK (Thr180/Tyr182), GAPDH, b-actin and goat anti-rabbit IgG-HRP Abs, as well as non-targeted SignalSilence Control siRNA were from Cell Signaling Technology (Danvers, MA, USA). Anti-pSGK (Ser422) goat Abs came from Santa Cruz Biotechnology (Santa Cruz, CA, USA), while mouse anti-goat IgG-HRP Abs were from Rockland Immunochemicals (Limerick, PA, USA). MaR1, RVD1 and RVD2 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Enhanced chemiluminescence kits were purchased from Thermo Scientific (Rockford, IL, USA). Cytokine ELISA kits (TNF, IL-10, IL-8 and IL-1b) were from eBioscience (San Diego, CA, USA). IL-12/23 p40 ELISA kits came from Boster Immunoleader (Pleasanton, CA, USA). The plasmids HA pcDNA3 and HA pcDNA3-GSK3b(S9A), were gifts from Jim Woodgett (Addgene; plasmids 10792, 14754). CREB siRNA was purchased from Dharmacon (Lafayette, CO, USA).
Preparation of human monocytes
Primary human monocytes were purified from anonymized, citrated whole blood by indirect magnetic monocyte isolation, as approved by the University of Louisville, Institutional Review Board (12.0346). This procedure routinely results in >95% pure CD14 + cells, as shown by flow cytometry. Human monocytes were cultured at 37 C and 5% CO 2 atmosphere, in complete RPMI plus or minus stimulating agents, as described below. Monocyte viability was evaluated by trypan blue exclusion.
Cytokine release by human monocytes
Primary human monocytes (200,000 cells/well) were stimulated or not with LPS and/or MaR1, RVD1 or RVD2, as described in the figure legends. Ethanol solvent controls, equivalent to the highest solvent concentration in the resolving stimulations, were included. MaR1, RVD1 or RVD2 was added 30 min prior to TLR4 stimulation with LPS. Cell-free supernatants were harvested at 20 h and assayed for cytokine levels by ELISA, according to the manufacturer's instructions.
Expression of GSK3 pathway molecules
Levels of Ser 536 phosphorylated NF-kB p65, Ser 9 phosphorylated GSK3b, as well as Ser 133 phosphorylated CREB, Ser 422 phosphorylated SGK-1, pSYK, pERK1/2, pSAPK/JNK, p38 MAPK, b-actin and GAPDH were determined by Western blot using whole-cell lysates (10 mg protein). Images were visualized by enhanced chemiluminescence and acquired using the ImageQuant LAS 4000 system (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Expression levels are presented as mean intensity ratios relative to a housekeeping gene, as determined by densitometry using Image J software (National Institutes of Health, Bethesda, MD, USA).
Pharmacological inhibition of GSK3 pathway
The contribution of GSK3b to the inhibition of TLR4induced cytokine induction in human monocytes was further explored through the use of the pharmaceutical inhibitor, SB216763. Monocytes were pre-treated with SB216763 for 2 h prior to LPS (1 mg/ml) stimulation with or without an additional pre-LPS stimulation with MaR1. DMSO (0.05%) and ethanol (as described above) solvent controls were included. Cell-free supernatants were assayed for cytokine levels by ELISA 20 h after the addition of LPS.
Transfection of GSK3(S9A) and siRNA
Transfection of monocytes with non-targeting control siRNA and siRNA-CREB, as well as plasmids pcDNA3-GSK3b(S9A) and pcDNA3 (empty vector control) was achieved by electroporation using Lonza Nucleofector technology (Allendale, NJ, USA), following the manufacturer's protocol. Transfected monocytes were stimulated with LPS on d 3 post transfection. Cell-free supernatants were assayed for IL-8 or IL-10 by ELISA 20 h after the addition of LPS.
Statistical analyses
Statistical significance between groups was evaluated by the analysis of variance and the Tukey multiple comparison test using the InStat program (GraphPad, San Diego, CA, USA). Differences between groups were considered significant at the level of P 0.05. Some Western blot-related data refer to representative blots. All other data are presented as the arithmetic mean AE SD of three biological replicates.
Results
Resolvin D1, resolvin D2 and maresin-1 suppress LPS-induced pro-inflammatory cytokines in primary human monocytes Initial experiments established that resolvins were highly efficient inhibitors of the release of IL-8, selected as a typical LPS-induced cytokine, from TLR4-engaged human monocytes across a broad range of concentrations ( Figure 1 ).
Subsequently, the ability of RVD1, RVD2 and MaR1 to inhibit inflammation-inducing cytokines (IL-1b, TNF; all P < 0.05) and the p40 sub-unit of the innate-adaptive bridging cytokine, IL-12 (all P < 0.05), was determined ( Figure 2 ). The IC 50 values for suppression of TNF, IL1b, IL-8 and IL-12 p40 are presented in Table 1 . Resolvins alone did not influence pro-inflammatory cytokine secretion in innate cells (Figures 1 and 2 ). Furthermore, resolvins had no significant influence on monocyte viability at the concentrations employed, as determined by trypan blue exclusion.
Resolvin D1, resolvin D2 and maresin-1 augment LPS-induced anti-inflammatory IL-10 release
Concomitant with the suppression of pro-inflammatory cytokines, RVD1, RVD2 and MaR1 each augmented the release of the anti-inflammatory cytokine, IL-10 (all P < 0.05) from TLR4-engaged innate cells, as shown in Figure 3 . Resolvins alone did not influence IL-10 production in human monocytes ( Figure 3 ).
Resolvin D1, resolvin D2 and maresin-1 phospho-inactivate GSK3 while activating CREB in LPS-stimulated innate cells
As can be seen in Figure 4 , RVD1, RVD2 and MaR1 each induced the efficient phosphorylation of the central mediator of inflammation, GSK3b, at Ser9-a potent inflammation inhibiting event. The activation status of SGK1, an anti-inflammatory kinase, 3 was similarly enhanced. Phosphorylation of SYK, a TLR ligand and inflammatory enhancer, 43 pERK1/2, pSAPK/JNK and/or p38 MAPK were unaffected (data not shown). However, RVD1, RVD2 and MaR1 all augmented the phosphorylation of CREB at Ser133 in TLR4-engaged innate cells, while the NF-kB (p65) signal was diminished. Importantly, resolvins alone did not influence the activation state of any of the inflammatory signaling molecules examined.
GSK3(S9A) and GSK3 blockade alter the anti-inflammatory properties of MaR1
As all data suggested that resolvins function similarly (Figures 1-4) , the mechanisms of resolvin-induced innate suppression were further elucidated using MaR1. The GSK3b inhibitor, SB216763, enhanced resolvin suppression of pro-inflammatory cytokine (IL-8; P < 0.05) production in the context of LPS concomitant with increased anti-inflammatory cytokine (IL-10; P < 0.001) secretion ( Figure 5A, B) . The augmentation by SB216763 suggests that inhibition of GSK3b by MaR1 is effective but incomplete. More importantly, however, MaR1 was unable to inhibit LPS-induced IL-8 production in monocytes transfected with pcDNA3-GSK3b(S9A) which expresses a GSK3b isoform that cannot be phosphorylatively inactivated ( Figure 5C ).
CREB silencing promotes a pro-inflammatory axis
As presented in Figure 6 , siRNA-mediated creb silencing confirmed the functional role of CREB in resolvinmediated augmentation of anti-inflammatory IL-10 production in TLR4-engaged monocytes. CREB levels were successfully knocked down by transfecting innate cells with creb-specific siRNA (Figure 6A, B) . Such creb silencing led to the enhancement of pro-inflammatory cytokine (IL-8; P < 0.05) release concomitant with suppression of anti-inflammatory cytokine (IL-10, P < 0.001) secretion in MaR1-and LPS-exposed monocytes ( Figure 6C , D).
Discussion
Several key studies have established a critical role for endogenous and exogenous docosahexaenoic acidderived lipid mediators, which appear to be share a degree of receptor commonality, [44] [45] [46] in the resolution of inflammation. 7, 8, 47, 48 Interestingly, Hsiao et al. have suggested that RVD1 may increase the concentration of the anti-inflammatory cytokine, IL-10, in the lungs of smoke-exposed mice. 49 We show that RVD1, RVD2 and MaR1 are each efficacious inhibitors of multiple pro-inflammatory cytokines (IL-1b, IL-8, TNF) produced by monocytes in response to stimulation with the classic TLR-4 agonist, LPS. We also show, for the first time, that all three resolvins suppress the innate/ adaptive bridging, T-cell-stimulating and angiogenic cytokine, IL-12 p40, while concomitantly increasing the expression of IL-10, the classic anti-inflammatory cytokine.
In order to harness and refine the anti-inflammatory therapeutic potential of resolvins, it is first necessary to understand their mechanisms of action. To this end, Nordgren et al. 28 have reported that while MaR1 pretreatment did not alter the activation of NF-kB, AP-1 or SP-1 in pollution particle-stimulated bronchial epithelial cells it did alter serum response element signaling. However, pollution particles may activate the innate response in a different manner than microbeassociated molecular patterns, and most studies have found an inhibitory effect of resolvins on the key proinflammatory transcriptional activator, NF-kB. [32] [33] [34] [35] Gilbert et al. 39 have reported that RVD1 promotes Akt activation and that the efficacy of RVD1 to suppress myocardial ischemia/reperfusion injury is abrogated by the PI3K inhibitor, LY-294002. Of the resolving mediators, RVE1 and LXA4 are among the better characterized, from a signaling perspective. Ohira et al. 41 have also reported that RVE1 can induce Akt-mTOR pathway activation, even in the absence of a primary pro-inflammatory mediator, in Chinese hamster ovary cells expressing the RVD1 receptor, Chem 23. 41 Prieto et al. 42 have established that LXA4 can activate the PI3K/Akt axis in macrophages. Wang et al. 16 have shown that the PI3K inhibitor (LY294002) blocks RVD1-induced expression of epithelial sodium channel a (ENaCa) in vitro and reduced the efficacy of RVD1 in suppressing pulmonary inflammation in a LPS-induced acute lung injury model. Other reports have also suggested RVD1 action may be mediated by PI3K. 40 PI3K is an activator of Akt, while Akt is an established phosphorylative inactivator of the central mediator of inflammation, GSK3b. 1, 2, 38 Furthermore, the ratios of NF-kB and CREB help direct the direction and intensity of the inflammatory response, with activity of the IL-10 gene being driven, in part, by interactions of CREB with the IL-10 cAMP-responsive element. 38 We have augmented the PI3k-Akt-related literature by establishing that RVD1, RVD2 and MaR1 each enhance the phosphorylation of GSK3b (inactivation) and CREB (activation), while reducing the amount of phosphorylated p65 relative to pCREB or GADPH. Interestingly, the activation state of SGK1, which we have recently established to be a potent antiinflammatory mediator in the context of TLRengagement, 3 was also enhanced by MaR1, RVD1 and RVD2. However, the phosphorylation state of SYK, a TLR ligand and inflammatory enhancer, 43 and several MAPK-related molecules was not influenced by resolvins. All Abs employed were established and commonly employed commercial preparations. However, cross-reactivity with non-target proteins remains a possibility. To this end, it was important to verify key immunoblot-derived data by a combination of pharmaceutical inhibition, gene silencing and gain-or loss-of-function approaches. Plasmid-derived GSK3bS9A, which cannot be phosphorylatively inactivated, abrogated the anti-inflammatory capability of MaR1. To further confirm the importance of CREB in resolvin-enhanced IL-10 response, siRNA-mediated creb silencing resulted in inflammatory polarization in the opposite direction to the GSK3b inhibitor SB216763, i.e., creb gene silencing enhanced proinflammatory cytokine (IL-8) release while suppressing MaR1 augmentation of anti-inflammatory IL-10 production in TLR4-engaged monocytes.
We have examined innate suppression in the context of a professional cytokine-producing cell type (monocytes) engaged by a highly potent TLR agonist (E. coli LPS), an in vitro system that has required the utilization of relatively high doses of resolving, with IC 50 values generally in the mM range. By comparison, inhibitory concentrations of resolving agonists used to suppress capsaicin (100 nM)-induced transient receptor potential vanilloid 1 currents in neurons (IC 50 & 0.5 nM) 50 or to reduce the TNF-induced IL-1b transcript signal in glioma cells (IC 50 & 50 pM) 51 are much lower. Others, however, have employed micromolar concentrations when determining the efficacy of pro-resolvins in the inhibition of cytokine production following direct engagement of TLRs in dedicated innate cells. 29, 30 Nevertheless, it remains to be seen if the same phenomena demonstrated in vitro herein occur in vivo.
There are many potential mechanisms of action of pro-resolving mediators, as recently reviewed. 46, [51] [52] [53] [54] We have focused on the TLR4 (LPS)-GSK3b axis and established that resolvins appear to induce the GSK3b anti-inflammatory axis leading to enhancement of the active form of the IL-10 transcriptional enhancer, CREB. Further elucidation of common and divergent mechanisms of action of such resolvins should facilitate the translation of RVD1, RVD2 and MaR1 for the amelioration of infection-driven inflammation and, perhaps, other conditions associated with dysregulation of the innate immune response. Indeed, it may even be possible to manipulate resolvin-related signaling events in order to up-or down-regulate the direction and intensity of the innate response, depending on the clinical necessity. 
